Enanta Pharmaceuticals, Inc.
Clinical trials sponsored by Enanta Pharmaceuticals, Inc., explained in plain language.
Biotech focused on antiviral and respiratory disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill for chronic hives enters first human safety tests Results expected Nov 2026 (estimated)
- New pill could help babies fight RSV faster Results expected Dec 2026 (estimated) May already have reported ↗
-
New pill could help babies fight RSV faster
Disease control Recruiting nowThis study tests an experimental oral drug called zelicapavir in 150 children aged 1 month to 3 years who have respiratory syncytial virus (RSV). The drug aims to stop the virus from multiplying and speed up recovery. Half the children will get the drug, half a placebo, and resea…
Phase 2 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill for chronic hives enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…
Phase 1 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC